The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances.
Immune checkpoint inhibitors revolutionize cancer therapy, yet challenges like efficacy variability and adverse events persist. 📊💉
October 9, 2025
Follow us
latest articles
Discover the newest research about AI innovations in 🧬 Genetics.
Automated data collection in cancer care: State of play among registries in the United Kingdom and Europe.
Automated coding in cancer registries: 12.8% use, 73.3% for pathology data, 87% efficiency reported. 📊💻
October 7, 2025
AI-Enhanced CRISPR Technology Aims to Accelerate Gene Therapy Development
AI-Enhanced CRISPR technology could speed up gene therapy development, making it accessible to more researchers. 🧬🤖
October 1, 2025
Application of Artificial Intelligence in Inborn Errors of Immunity Identification and Management: Past, Present, and Future-A Systematic Review.
AI enhances diagnosis of inborn errors of immunity, improving accuracy and reducing costs. Key findings from PubMed review. 🤖💉
September 13, 2025
Artificial Intelligence and Network Medicine: Path to Precision Medicine.
AI and Network Medicine: Enhancing Precision Medicine through Deep Learning Techniques 🤖🔬
September 9, 2025
Residual disease in NPM1-mutated acute myeloid leukemia.
Exploring NPM1-mutated AML: MRD detection methods, AI’s role, and challenges in clinical integration. 🧬🔬
September 7, 2025
New AI Tools from Penn Enhance Kidney Disease Treatment
New AI tools from Penn enhance kidney disease treatment by analyzing cellular data for personalized therapies. 🧬💊
September 6, 2025
Lung lobe segmentation: performance of open-source MOOSE, TotalSegmentator, and LungMask models compared to a local in-house model.
Lung lobe segmentation tools evaluated: TotalSegmentator excels, while data diversity enhances model accuracy. 📊🫁
September 5, 2025
Population health management of human phenotype ontology.
Population health management integrates Human Phenotype Ontology for improved health outcomes. Key findings on AI, genomics, and ethical stewardship. 📊🌍
August 30, 2025
The Evolving Landscape of Novel and Old Biomarkers in Localized High-Risk Prostate Cancer: State of the Art, Clinical Utility, and Limitations Toward Precision Oncology.
Exploring biomarkers in high-risk prostate cancer: 50-75% relapse rate post-treatment. Genomic profiling enhances precision oncology. 📊🔬
August 28, 2025